Navigation Links
FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
Date:2/6/2008

ency (EMEA) for Cimzia(R) in the treatment of RA is ongoing, with filing planned in the first half of 2008.

In September 2007, Cimzia(R) was approved in Switzerland for the treatment of Crohn's disease and it was launched in January 2008.

About Rheumatoid Arthritis

RA is a progressive autoimmune disease that causes chronic inflammation of the joints. It is estimated that five million people suffer from RA globally, with 0.3 percent to 1 percent of the population in industrialized countries suffering from the disease. Women are three times more likely to be affected than men. Although it can affect people of all ages, the onset of RA usually occurs between the ages of 35-55.

Traditional treatments for RA include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids and disease-modifying antirheumatic drugs (DMARDs), with biological therapies a more recent addition.

About UCB

UCB, Brussels, Belgium (http://www.ucb-group.com) is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. UCB focuses on securing a leading position in severe disease categories. Employing around 12,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. UCB S.A. is listed on Euronext Brussels.

UCB Forward-Looking Statement

This news release contains forward-looking statements that involve risks and uncertainties, including statements with respect to the development and commercialization of certolizumab pegol. Among the factors that could cause actual results to differ materially from those indicated by such forward- looking statements are: the results of research, development and clinical trial
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
2. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
5. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
6. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
7. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
8. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
9. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
10. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
11. AEterna Zentaris Announces Outcome of Managements Strategic Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Dallas, Texas (PRWEB) , ... July 31, 2015 ... ... research report, offering competitive market analysis and premium industry insights on the global ... challenges, based on a collective study of vivid market scenarios and analysis of ...
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm is proud to announce ... gluten in foods, has been accepted by AOAC International as Official First Action ... Fermented Cereal-Based Products by R5 Competitive ELISA,” based on a specific monoclonal antibody ...
(Date:7/30/2015)... 2015 AACC welcomed thousands of medical ... Annual Meeting & Clinical Lab Expo in ... meeting showcased revolutionary advancements in clinical testing technology ... providers to diagnose patients quickly and accurately and ... As of Wednesday, July 29, more ...
(Date:7/30/2015)... ... July 30, 2015 , ... Tronics, a ... Sales & Marketing Director. , With more than 25 years of experience ... reinforcing Tronics’ business development activities worldwide. He brings to the company his strong ...
Breaking Biology Technology:Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2
... PITTSBURGH, Nov. 21, 2011   ParentPlus LLC, a ... and proprietary human fertility technologies, is entering into a ... of further development of new products for IUI (Intra-Uterine ... pleased to announce the signing of this agreement which ...
... New Report Added in ResearchMoz Reports Database - ... Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic ... Research . GBI Researchs report, ... Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive ...
... Japan, November 18, 2011 - A research group from ... and Fujitsu Limited today announced that research results obtained ... Bell Prize, Peak-Performance at SC11, the International Conference for ... in Seattle, on November 17 (US Pacific Standard Time). ...
Cached Biology Technology:Pittsburgh Based ParentPlus Enters Collaboration with Vitrolife 2ResearchMoz: Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market 2ResearchMoz: Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market 3ResearchMoz: Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market 4'K computer' research results awarded ACM Gordon Bell Prize 2
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 ... sobre Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 ... . La conferencia celebra su décimo ... se ha convertido en una de las reuniones anuales ... ,ómicas, y es una de las conferencias científicas más ...
(Date:7/31/2015)... SHENZHEN, China , 31. Juli 2015 Die ... ) wird von BGI veranstaltet und findet vom ... Shenzhen, China , statt. ... Jubiläum. Seit ihrem Start 2006 ist die ICG ... Bereich „omik" geworden. Sie ist eines der dynamischsten, ...
(Date:7/27/2015)... , July 27, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that Huawei has selected ... solution for its stylish smartwatch. Huawei chose the ... reliability, low power and highly responsive human interface ... Huawei designers also required a classic round watch ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... EVANSTON, Ill. --- A Northwestern University research team ... could be used to deliver chemotherapy drugs locally ... removed. The flexible microfilm device, which ... be customized easily into different shapes, has the ...
... planning of the preparatory activities for a new tentative ... satellite. On 7 September, preparatory activities for the ... Russia were stopped by Eurockot due to an anomaly ... and navigation subsystem of the launcher,s Upper Stage Breeze ...
... reveal an electromagnetic marker that predicts a patient,s ... "Such biomarkers that identify who will benefit ... minimize trial-and-error prescribing and speed delivery of care ... Carlos Zarate, M.D., of the National Institute of ...
Cached Biology News:Nanodiamond drug device could transform cancer treatment 2Nanodiamond drug device could transform cancer treatment 3Millisecond brain signals predict response to fast-acting antidepressant 2
Request Info...
Please email us with project details and we will respond within 24 hours to your query!...
Makes gels easy to load and track during electrophoresis. 10X concentrate of Bromophenol Blue, glycerol solution....
Request Info...
Biology Products: